Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer

1 Jan 2022

Abstract excerpt

Rationale: Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with a dismal 5-year survival less than 10%. Most patients with PDAC exhibit poor response to single-agent immunotherapy. Multimodal therapies targeting mechanisms of resistance to immunotherapy are urgently needed. We found that the class IIa histone deacetylase (HDAC) member, HDAC5 is downregulated in multiple solid tumors and its level were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Histone Deacetylase Inhibitors Research
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35265200
DOI: 10.7150/thno.69444

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancerPMID 35265200Read ↗

B4GALT5 inhibits CD8+ T-cell response by downregulating MHC-I level through ERAD pathway in PDACSemantic proximity Read ↗

Comprehensive immunohistochemical analysis of histone deacetylases in pancreatic neuroendocrine tumors: HDAC5 as a predictor of poor clinical outcomeSemantic proximity Read ↗

Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner.Semantic proximity Read ↗

BAP1 regulates HSF1 activity and cancer immunity in pancreatic cancerSemantic proximity Read ↗

Inhibition of SUMOylation Induces Adaptive Antitumor Immunity against Pancreatic Cancer through Multiple Effects on the Tumor MicroenvironmentSemantic proximity Read ↗

Histone Deacetylase Inhibitors Restore Cancer Cell Sensitivity towards T Lymphocytes Mediated Cytotoxicity in Pancreatic CancerSemantic proximity Read ↗

A pan‐cancer analysis identifies HDAC11 as an immunological and prognostic biomarkerSemantic proximity Read ↗

Pancancer analysis uncovers an immunological role and prognostic value of the m6A reader IGF2BP2 in pancreatic cancerSemantic proximity Read ↗

Identification of a novel immune checkpoint molecule V‐set immunoglobulin domain‐containing 4 that leads to impaired immunity infiltration in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

KLF5 controls subtype-independent highly interactive enhancers in pancreatic cancer to regulate cell survivalSemantic proximity Read ↗

Plectin promotes an aggressive phenotype and represses cytotoxic T cell activity in pancreatic cancerSemantic proximity Read ↗

Genomic analysis reveals HDAC1 regulates clinically relevant transcriptional programs in pancreatic cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.